Kazakhstan Clinical Evidence Acceptance: Foreign Data, Dual Pathways and the 2027 Transition Window

1. Key takeaways

The national pathway in Kazakhstan can accept existing foreign clinical data submitted by the applicant, without repeating clinical studies inside the Union — this is the most substantive cost advantage the national pathway holds over the Union pathway. The Union pathway instead follows the review framework of Decision No. 46, whose requirements for clinical evidence and its triggers for local studies form a system of their own. Whichever route is chosen, the clinical evidence must close a loop with the risk management documentation and the claims in the instructions for use: every clinical benefit claimed in the labeling must be traceable to specific evidence. Companies that design the evidence package around this loop, rather than assembling reports and claims independently, pass review with fewer rounds and defend their labeling far more easily during the life of the certificate.

2. Legal basis

3. Expert insights

Insight one: the acceptability of foreign clinical data is an undervalued dividend of the national pathway. For Chinese manufacturers holding a European clinical evaluation report supporting CE marking or clinical data from the United States, the national pathway allows those materials to be carried over directly, eliminating the time and cost of conducting clinical studies inside the Union — both savings are of a different order of magnitude. Within the window ending on December 31, 2027, this dividend deserves to be realized as a priority, because the terms of access to the national route are tied to the transition period agreed in the protocol signed in December 2025.

Insight two: foreign data cannot simply be transplanted; an applicability justification is required. The submission must establish three things for the foreign clinical data: equivalence between the device covered by the data and the device under evaluation, the applicability of the population and clinical practice to the Kazakh setting, and the quality and completeness of the data themselves. Without this justification, even excellent foreign data can draw a request for supplementation, wasting part of the advantage the pathway was chosen for. The justification should be drafted by the same authors who prepared the original clinical evaluation, so that the reasoning in the two documents is visibly one and the same.

Insight three: the correspondence between claims and evidence is the central lever of the review. The reviewer compares each clinical benefit claim in the instructions for use against the evidence in the dossier, claim by claim. Many claims with thin evidence is the scenario most likely to trigger deficiency letters. The GRZAN recommendation is to fix the evidence first and only then fix the claims, never the reverse, and that boundary must be agreed internally before drafting begins, not negotiated with the reviewer afterward. A claims register that records each claim, its evidence reference and its owner keeps this discipline alive through revisions.

Insight four: high-risk devices and novel mechanisms are the main trigger zone for local studies. For implantable products, life-supporting products and devices with new mechanisms of action, the expectations for clinical evidence rise on either pathway. The clinical plan for such products should be discussed with the expert organization at the project initiation stage, since agreement on the evidence strategy before submission is the only reliable way to avoid an open-ended exchange of questions late in the review.

Insight five: one base set of clinical materials can serve both pathways, but the argument structures differ. The base materials — the clinical evaluation report, the literature, the raw data — can be shared; the argument structure must be organized according to the requirements of each pathway. This is the most delicate part of any evidence reuse strategy, and mapping the two argument structures early prevents expensive rework when a product is filed on both routes.

4. Practical recommendations

1. Prioritize realizing the foreign clinical data dividend on the national pathway, scheduling filing within the window ending December 31, 2027.
2. Attach an applicability justification to foreign data covering device equivalence, population applicability and data quality.
3. Fix the evidence first and then the claims, so that every clinical benefit in the labeling is traceable item by item.
4. Discuss the clinical plan for high-risk and novel-mechanism products with the expert organization at the initiation stage.
5. Organize the evidence package as shared base materials with pathway-specific argument structures.

5. Verification checklist

• □ The pathway (national or Union) and the corresponding clinical evidence requirements are confirmed
• □ Foreign clinical data are accompanied by an applicability justification (equivalence, population applicability, data quality)
• □ Every clinical benefit claim in the instructions for use is traceable to specific evidence
• □ The clinical plan for high-risk and novel-mechanism products has been pre-agreed
• □ The package of shared base materials and separate argument structures is established
• □ National pathway projects are scheduled within the window ending December 31, 2027

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering clinical evidence strategy, pathway selection and expert review liaison. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.